You are here

Home » Content

COMPARATIVE STUDY OF DAPSONE AND CYCLOPHOSPHAMIDE ON TREATMENT OF PAPILLOMA SKIN CANCER

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2013

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
In the present study, anti-cancer property of Dapsone was evaluated against 7, 12-dimethyl benz(a)anthracene (DMBA) induced skin tumorigenesis in Swiss albino mice. A single topical application of 7,12-dimethyl benz(a)anthracene (100 u.g/100 u.l of acetone), followed 2 weeks later by repeated application of croton oil (1% in acetone two times a week) for 8 weeks exhibited 100 percent tumor incidence (group IV). In contrast, animals treated orally with Dapsone (group V) and Cyclophosphamide (group VI) exhibited 40, 50 per cent tumor incidence, which significantly higher than 100% tumor incidence in the group IV (control). The cumulative number of papillomas during the observation period of 8 weeks was significantly decreased in the groups V and VI in compare to 25 cumulative numbers of papillomas in carcinogen control group. The tumor burden and tumor yield of V and VI group was significantly lesser (1.89, 2.9 and 1.82, 2.7) as compared to DMBA/ croton oil treated control (3.8 and 3.8). The study has revealed the inhibition of dimethylebenz (a) anthracene (DMBA)/croton oil induced skin tumorigenesis in Swiss albino mice by Dapsone treatment comparison to Cyclophosphamide.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-comparative-study-dapsone-and-cyclophosphamide-treatment-papilloma-skin-cancer.pdf
  • 4
385
392
  • English

REFERENCES

References: 

1. Marks R: An overview of skin cancers. Incidence and causation. Cancer 1995; 75: 607-12.
2. Kasper DL, Braunwald E, Fauci A, et al.: Harrison's Principles of Internal Medicine, 16th ed. New York: McGraw-Hill
2005; 2066.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H: Classification of papillomaviruses. Virology 2004; 324: 17¬27.
4. Herbst LH, Lenz J, Van Doorslaer K, Chen Z, Stacy BA, Wellehan JF Jr, Manire CA and Burk RD: Genomic characterization of two novel reptilian papillomaviruses, Chelonia mydas papillomavirus 1 and Caretta caretta papillomavirus 1. Virology 2009; 383: 131-5.
5. Drury SE, Gough RE, McArthur S and Jessop M: Detection of herpesvirus-like and papillomavirus-like particles associated with diseases of tortoises. Vet Rec 1998; 143: 639.
6. Lange CE, Favrot C, Ackermann M, Gull J, Vetsch E and Tobler K: Novel snake papillomavirus does not cluster with other non-mammalian papillomaviruses. Virol J
2011; 8: 436.
7. Munoza N, Castellsagueb X, Berrington de Gonzalezc A and Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24: S1-S10.
8. Mistry N, Wibom C and Evander M: Cutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropism. Virol J
2008; 5: 118.
9. Doorbar J: The papillomavirus life cycle". J Clin Virol 2005; 32: S7-15.
10. Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine, by Sabatine, 3rd Edition.
11. Croft AM: Malaria: prevention in travellers. Clinical evidence 2007.
12. Alkadi HO: Antimalarial drug toxicity: a review. Chemotherapy 2007; 53: 385-391.
13. Begon E, Chosidow O and Wolkenstein P: "Disulone". Ann Dermatol Venereol (in French) 2004; 131: 1062-73.
14. Uetrecht JP: Myeloperoxidase as a generator of drug free radicals. Biochem
Soc Symp 1995; 61: 163-70.
15. Takimoto CH and Calvo E: Principles of Oncologic Pharmacotherapy in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed 2008.
16. Shanafelt TD, Lin T, Geyer SM, et al.: Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;
109: 2291-8.
Available Online at www.ijprbs.com
Research
Articl
e CODEN: IJPRNK
Shashi Shekhar Singh, IJPRBS, 2013; Volume 2(4): 385-392
17. Young SD, Whissell M, Noble JC, et al.:
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and
ISSN: 2277-8713 IJPRBS
rofecoxib in patients with advanced solid tumors. Clinical Cancer Research 2006; 12:
3092-8.

Thank you for copying data from http://www.arastirmax.com